Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Authorized Generics Do Not Deter Patent Challenges, FTC Says, But May Be Used To Delay Competition

Executive Summary

Authorized generics modestly reduce drug prices during the first 180 days of generic competition and substantially undercut the revenues of competing generic firms, according to the Federal Trade Commission.

You may also be interested in...

Authorized Generics: Launches And Promises

Brand-Generic "Pay-For-Delay" Settlements Jump 63% In FY 2010

As a proportion of total settlements reported to FTC, however, the ones involving compensation to the generic firm remained the same.

Authorized Generic "Interim" Report From FTC Offers Little Legislative Guidance

FTC commissioners issue separate statements on a report that does not address the long-term effects of authorized generics.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts